Tubulis–Andera Partners: investment, 202205 financing round Series B totalling €60m incl new + lead investor Andera Partners |
2022-05-03 |
Tubulis–Bavaria (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Wachstumsfonds Bayern 2 |
2022-05-03 |
Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners |
2022-05-03 |
Tubulis–BPCE: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Seventure Partners |
2022-05-03 |
Tubulis–Evotec: investment, 202205 financing round Series B totalling €60m incl new + co-investor Evotec |
2022-05-03 |
Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+ |
2022-05-03 |
Tubulis–Germany (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Coparion |
2022-05-03 |
Tubulis–High-Tech Gründerfonds: investment, 202205 financing round Series B totalling €60m incl existing + co-investor HTGF |
2022-05-03 |
Tubulis–Occident Group: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident |
2022-05-03 |
Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners |
2022-05-03 |
Boehringer–CDR-Life: ophthalmic, 202204 collab development existent of antibody fragment-based therapeutic CDR202 for macular degeneration |
2022-04-13 |
CDR-Life–Argot Partners: public relations, 202204 service existent media contact Argot Partners |
2022-04-13 |
CDR-Life–Jeito Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor Jeito Capital |
2022-04-13 |
CDR-Life–Omega Funds: investment, 202204 financing round Series A totalling $76m incl co-investor Omega Funds |
2022-04-13 |
CDR-Life–RA Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor RA Capital Management |
2022-04-13 |
CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital |
2022-04-13 |
Cimeio Therapeutics–Versant Ventures: investment, 202204– Series A $50m commitment at launch from Versant Ventures |
2022-04-13 |
Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED |
2022-04-12 |
Avi Medical–Balderton Capital: investment, 202204 financing round Serise B totalling €50m incl lead investor Balderton Capital |
2022-04-06 |
Avi Medical–SEVERAL: investment, 202204 financing round Series B €50m led by Balderton Capital |
2022-04-06 |
IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker |
2022-04-06 |
Regeneron–ViGeneron: gene therapy, 202204– collab + option agreem to develop vgAAV-based therapeutics for one inherited retinal disease target |
2022-04-06 |
Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza |
2022-04-05 |
Optimal Industrial–Bruker: investment, 202204 acquisition €na of Optimal Industrial Automation + Technologies by Bruker |
2022-04-05 |
Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m |
2022-04-04 |
Andes–Bayer: investment, 202204 existent portfolio company of Leaps by Bayer |
2022-04-01 |
Ebenbuild–Bavaria (govt): investment, 202203 seed financing round totalling €2.5m incl co-lead investor Bayern Kapital |
2022-03-31 |
Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF |
2022-03-31 |
Ebenbuild–OTHER: investment, 202203 seed financing round totalling €2.5m incl well-known business angels as co-investors |
2022-03-31 |
Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels |
2022-03-31 |
Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan |
2022-03-30 |
VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m |
2022-03-30 |
Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation |
2022-03-29 |
Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer |
2022-03-22 |
ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada |
2022-03-22 |
ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc |
2022-03-22 |
ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc |
2022-03-22 |
Nucleai MD–Debiopharm: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Debiopharm |
2022-03-22 |
Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures |
2022-03-22 |
Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant |
2022-03-21 |
Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund |
2022-03-16 |
Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion |
2022-03-16 |
BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients |
2022-03-15 |
Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl |
2022-03-14 |
Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH |
2022-03-14 |
Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank |
2022-03-14 |
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH |
2022-03-14 |
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH |
2022-03-14 |
Ayoxxa–Prosnav Capital: investment, 202203 financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital |
2022-03-14 |
Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office |
2022-03-14 |
Ayoxxa–SEVERAL: investment, 202203 financing round providing runway for 3-5 years led by new investor Prosnav Capital |
2022-03-14 |
Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners |
2022-03-14 |
FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED |
2022-03-14 |
Ginkgo Bioworks–FGen: screening technology, 202203 collab existent for several years |
2022-03-14 |
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Matthias Bissinger |
2022-03-10 |
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Philipp Baaske |
2022-03-10 |
Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech |
2022-03-10 |
Scenic Biotech–BioMedPartners: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor BioMedPartners |
2022-03-10 |
Scenic Biotech–SEVERAL: investment, 202203 financing round Series A €28m co-led by Eir Ventures + BioMedPartners + Vesalius Biocapital |
2022-03-10 |
Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders |
2022-03-09 |
NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity |
2022-03-08 |
Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m |
2022-03-07 |
ArrePath–Boehringer: investment, 202203 seed financing round totalling $20m incl co-lead investor BIVF |
2022-03-03 |
ArrePath–SEVERAL: investment, 202203 seed financing round $20m co-led by BIVF + Insight Partners + Innospark Ventures |
2022-03-03 |
Epsilogen–Novartis: investment, 202203 financing round Series B totalling £30.75m incl new + lead investor Novartis Venture Fund |
2022-03-02 |
Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund |
2022-03-02 |
BioEcho Life Sciences–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners |
2022-03-01 |
In Ovo–ABN AMRO: investment, 202203 financing round totalling €34m incl new investor ABN AMRO |
2022-03-01 |
In Ovo–ECBF: investment, 202203 financing round totalling €34m incl new investor ECBF |
2022-03-01 |
In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik |
2022-03-01 |
In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al |
2022-03-01 |
Aphea.Bio–ECBF: investment, 202202 existent investment of ECBF |
2022-02-23 |
Ampersand–Recipharm: investment, 202202– acquisition of Vibalogics by Recipharma AB ANNOUNCED |
2022-02-18 |
Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al |
2022-02-16 |
Climedo Health–SEVERAL: investment, 202202 seed financing round €5m led by Nauta Capital |
2022-02-16 |
ITM–Grand Pharma: investment, 202202 equity investment €25m from strategic partner Grand Pharmaceutical Group Ltd |
2022-02-16 |
SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital |
2022-02-16 |
XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al |
2022-02-16 |
c-LEcta–Kerry Group: investment, 202202 acquisition 92% for €137m with management to retain balance of shares |
2022-02-15 |
IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec |
2022-02-15 |
NMD Pharma–Roche: investment, 202202 financing round totalling €35m incl existing + co-investor Roche Venture Fund |
2022-02-15 |
NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors |
2022-02-15 |
Sequana Medical –Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund |
2022-02-15 |
Green Elephant Biotech–Hessen (govt): investment, 202201 pre-seed financing round totalling mid-6-digit € incl lead investor BMH |
2022-02-11 |
Green Elephant Biotech–OTHER: investment, 202201 pre-seed financing round totalling mid-6-digit € incl business angels as co-investors |
2022-02-11 |
Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels |
2022-02-11 |
Celeris Therapeutics–Apex Ventures: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Apex Ventures |
2022-02-10 |
Celeris Therapeutics–i&i Biotech Fund: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor i&i Biotech Fund |
2022-02-10 |
Celeris Therapeutics–Longevitytech.fund: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor Longevitytech.fund |
2022-02-10 |
Celeris Therapeutics–Pace Ventures Enigma: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Pace Ventures Enigma |
2022-02-10 |
Celeris Therapeutics–R42 Group: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor R42 Group |
2022-02-10 |
Celeris Therapeutics–SEVERAL: investment, 202202 seed financing round $4.4m led by Pace Ventures Enigma + i&i Biotech Fund + Apex Ventures |
2022-02-10 |
Haya Therapeutics–4See Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor 4See Ventures |
2022-02-09 |
Haya Therapeutics–Apollo Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Apollo Health Ventures |
2022-02-09 |
Haya Therapeutics–Bernina BioInvest: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Bernina BioInvest |
2022-02-09 |
Haya Therapeutics–Broadview Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Broadview Ventures |
2022-02-09 |
Haya Therapeutics–Humboldt Fund: investment, 202202 seed financing round extension totalling $5m incl new + lead investor Humboldt Fund |
2022-02-09 |
Haya Therapeutics–Schroders: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Schroder Adveq |
2022-02-09 |
Haya Therapeutics–SEVERAL: investment, 202202 seed financing round extension $5m led by new investor Humboldt Fund |
2022-02-09 |
Haya Therapeutics–Viva Biotech: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Viva BioInnovator |
2022-02-09 |